Results of the phase III, randomized, double-blind GO-VIBRANT study show that patients with psoriatic arthritis (PsA) treated with intravenous golimumab 2 mg/kg (n = 241) had greater improvements in the signs and symptoms of the disease at week 14 and less radiographic progression at week 24 than those who received intraveous placebo (n = 239). 75.1% of those in the golimumab arm achieved ≥20% improvement according to ACR criteria (ACR20) at week 14, compared with 21.8% of the placebo group.